2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Apical Sodium-Dependent Bile Acid Transporter
  5. Apical Sodium-Dependent Bile Acid Transporter Inhibitor

Apical Sodium-Dependent Bile Acid Transporter Inhibitor

Apical Sodium-Dependent Bile Acid Transporter Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-109120
    Odevixibat
    		Inhibitor 99.92%
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
  • HY-15790
    Elobixibat
    		Inhibitor 99.91%
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
  • HY-16747
    Maralixibat chloride
    		Inhibitor 99.08%
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.
  • HY-168523
    S1647
    		Inhibitor
    S1647 is a ASBT and SOAT dual inhibitor. S1647 can be used in the study of intrahepatic cholestasis, cholestatic pruritus, and obstipation.
  • HY-148795
    Ritivixibat
    		Inhibitor
    Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
  • HY-109120S
    Odevixibat-d5
    		Inhibitor
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
  • HY-15790H
    (S)-Elobixibat
    		Inhibitor 98.75%
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
  • HY-109120S1
    Odevixibat-13C6
    		Inhibitor
    Odevixibat-13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
  • HY-15790R
    Elobixibat (Standard)
    		Inhibitor
    Elobixibat (Standard) is the analytical standard of Elobixibat. This product is intended for research and analytical applications. Elobixibat is a potent ileal bile acid transporter (IBAT) inhibitor with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.